Itay&Beyond

Itay&Beyond is a pioneering biotech startup revolutionizing neuropsychiatric drug discovery through its groundbreaking platform. Founded by Dr. Nisim Perets, Shmulik Bezalel, and Boaz Goldman, and inspired by Bezalel's personal experience with autism, the company is driven by the urgent need for more effective treatments in neuropsychiatry. Our technology, validated in a 200-patient study at Hadassah Medical Center, combines patient-derived brain organoids, a bio-dynamic processing unit, and advanced AI analysis to dramatically improve drug efficacy predictions. These 3-dimensional brain clones, derived from human stem cells, can perform 70,000 electrical signals per second, providing an unprecedented model for understanding drug effects. Our adaptable and scalable system reads functional outputs and monitors responses to various compounds over time, yielding precise predictions of drug efficacy for specific populations with neurological and psychiatric disorders. Itay&Beyond's vision is to transform lives by breaking through barriers in neuropsychiatric drug discovery. By partnering with pharmaceutical companies and Contract Research Organizations (CROs), we offer programs for patient stratification, population expansion, drug repurposing, and new compound discovery. Our ability to predict drug efficacy before clinical trials accelerates the development of effective treatments, providing new hope for millions worldwide affected by these disorders. Learn more: https://itayandbeyond.com/